Pliant Therapeutics Announces Positive Long-Term Data from :

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care...

Related Keywords

, Lisah Lancaster , Toby Maher , Los Angeles , Christopher Keenan , Group Demonstrated Treatment Effects Including Durable Improvements , Corporate Communications , Youtube , Drug Administration , Vanderbilt University Medical Center , Facebook , European Medicines Agency , Nasdaq , Twitter , Bexotegrast Clinical Development Next , Pliant Therapeutics Inc , Linkedin , University Of Southern California , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Keck School , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act , Financial Condition , Annual Report , Fast Track Designation , Orphan Drug Designation , Media Contact , Investor Relations , Adv Respir , Respir Rev , Nasdaq Plrx , Nc ,